Acute Pain - Pipeline Review, H2 2016

Date: August 10, 2016
Pages: 194
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: A8697732578EN
Leaflet:

Download PDF Leaflet

Acute Pain - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Acute Pain - Pipeline Review, H2 2016’, provides an overview of the Acute Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Acute Pain
  • The report reviews pipeline therapeutics for Acute Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Acute Pain therapeutics and enlists all their major and minor projects
  • The report assesses Acute Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Acute Pain
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Acute Pain
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Acute Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Acute Pain Overview
Therapeutics Development
Pipeline Products for Acute Pain - Overview
Pipeline Products for Acute Pain - Comparative Analysis
Acute Pain - Therapeutics under Development by Companies
Acute Pain - Therapeutics under Investigation by Universities/Institutes
Acute Pain - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Acute Pain - Products under Development by Companies
Acute Pain - Products under Investigation by Universities/Institutes
Acute Pain - Companies Involved in Therapeutics Development
AcelRx Pharmaceuticals, Inc.
Adynxx, Inc.
Amorsa Therapeutics Inc.
AnaBios Corporation
Anavex Life Sciences Corp.
AngioChem Inc.
Antibe Therapeutics, Inc.
AskAt Inc.
Cara Therapeutics, Inc.
Centrexion Therapeutics Corp
Charleston Laboratories, Inc.
ChironWells GmbH
Crescita Therapeutics Inc.
Cytogel Pharma, LLC
Dompe Farmaceutici S.p.A.
Grunenthal GmbH
Iroko Pharmaceuticals, LLC
KemPharm, Inc.
KPI Therapeutics, Inc.
Laboratorios Del Dr. Esteve S.A.
Mallinckrodt Plc
Nanomerics Ltd
Nanotherapeutics, Inc.
Orbis Biosciences Inc
Orexo AB
Orion Oyj
Pacira Pharmaceuticals, Inc.
Phosphagenics Limited
Recro Pharma, Inc.
Scilex Pharmaceuticals, Inc.
Shulov Innovative Science Ltd.
Syntrix Biosystems, Inc.
Thar Pharmaceuticals, Inc.
Trevena, Inc.
Yungjin Pharm. Co., Ltd.
Acute Pain - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(acetaminophen + benzhydrocodone hydrochloride) IR - Drug Profile
(acetaminophen + hydrocodone bitartarate) ER - Drug Profile
(acetaminophen + tramadol hydrochloride) SR - Drug Profile
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile
(celecoxib + tramadol hydrochloride) - Drug Profile
AAT-076 - Drug Profile
alfentanil hydrochloride - Drug Profile
AMS-410 FA - Drug Profile
ANAVEX-1037 - Drug Profile
ANAVEX-1066 - Drug Profile
ANAVEX-1067 - Drug Profile
ANAVEX-1079 - Drug Profile
ANAVEX-1519 - Drug Profile
ANG-2002 - Drug Profile
ARX-04 - Drug Profile
ATB-352 - Drug Profile
AYX-1 - Drug Profile
BBI-11008 - Drug Profile
celecoxib - Drug Profile
CL-108 - Drug Profile
CR-4056 - Drug Profile
Cyt-1010 - Drug Profile
dexmedetomidine hydrochloride - Drug Profile
DF-2593A - Drug Profile
difelikefalin - Drug Profile
Drug for Acute Pain - Drug Profile
ECP-1014 - Drug Profile
ET-1 - Drug Profile
FY-101C - Drug Profile
FY-103B - Drug Profile
grapiprant - Drug Profile
HPI-201 - Drug Profile
HS-731 - Drug Profile
ibuprofen - Drug Profile
ibuprofen - Drug Profile
ibuprofen - Drug Profile
ketamine hydrochloride - Drug Profile
lidocaine hydrochloride - Drug Profile
meloxicam - Drug Profile
meloxicam - Drug Profile
meloxicam ER - Drug Profile
Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain - Drug Profile
MR-309 - Drug Profile
NM-0127 - Drug Profile
oliceridine - Drug Profile
Omnitram - Drug Profile
Peptides to Target TRPV1 for Pain and Itch - Drug Profile
prednisone - Drug Profile
Prostatic Acid Phosphatase - Drug Profile
RO-656570 - Drug Profile
Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile
Small Molecules to Block Nav 1.7 for Pain - Drug Profile
Small Molecules to Block Nav 1.8 for Pain - Drug Profile
Synthetic Peptides to Target Mu Opioid Receptor and Delta Opioid Receptor for Pain - Drug Profile
T-109 - Drug Profile
tapentadol hydrochloride - Drug Profile
TRV-734 - Drug Profile
U-2902 - Drug Profile
VPX-595 - Drug Profile
ZEP-3 - Drug Profile
Acute Pain - Dormant Projects
Acute Pain - Discontinued Products
Acute Pain - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Acute Pain, H2 2016
Number of Products under Development for Acute Pain - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd.1)
Number of Products under Development by Companies, H2 2016 (Contd.2)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Comparative Analysis by Unknown Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd.1)
Products under Development by Companies, H2 2016 (Contd.2)
Products under Development by Companies, H2 2016 (Contd.3)
Products under Investigation by Universities/Institutes, H2 2016
Acute Pain - Pipeline by AcelRx Pharmaceuticals, Inc., H2 2016
Acute Pain - Pipeline by Adynxx, Inc., H2 2016
Acute Pain - Pipeline by Amorsa Therapeutics Inc., H2 2016
Acute Pain - Pipeline by AnaBios Corporation, H2 2016
Acute Pain - Pipeline by Anavex Life Sciences Corp., H2 2016
Acute Pain - Pipeline by AngioChem Inc., H2 2016
Acute Pain - Pipeline by Antibe Therapeutics, Inc., H2 2016
Acute Pain - Pipeline by AskAt Inc., H2 2016
Acute Pain - Pipeline by Cara Therapeutics, Inc., H2 2016
Acute Pain - Pipeline by Centrexion Therapeutics Corp, H2 2016
Acute Pain - Pipeline by Charleston Laboratories, Inc., H2 2016
Acute Pain - Pipeline by ChironWells GmbH, H2 2016
Acute Pain - Pipeline by Crescita Therapeutics Inc., H2 2016
Acute Pain - Pipeline by Cytogel Pharma, LLC, H2 2016
Acute Pain - Pipeline by Dompe Farmaceutici S.p.A., H2 2016
Acute Pain - Pipeline by Grunenthal GmbH, H2 2016
Acute Pain - Pipeline by Iroko Pharmaceuticals, LLC, H2 2016
Acute Pain - Pipeline by KemPharm, Inc., H2 2016
Acute Pain - Pipeline by KPI Therapeutics, Inc., H2 2016
Acute Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016
Acute Pain - Pipeline by Mallinckrodt Plc, H2 2016
Acute Pain - Pipeline by Nanomerics Ltd, H2 2016
Acute Pain - Pipeline by Nanotherapeutics, Inc., H2 2016
Acute Pain - Pipeline by Orbis Biosciences Inc, H2 2016
Acute Pain - Pipeline by Orexo AB, H2 2016
Acute Pain - Pipeline by Orion Oyj, H2 2016
Acute Pain - Pipeline by Pacira Pharmaceuticals, Inc., H2 2016
Acute Pain - Pipeline by Phosphagenics Limited, H2 2016
Acute Pain - Pipeline by Recro Pharma, Inc., H2 2016
Acute Pain - Pipeline by Scilex Pharmaceuticals, Inc., H2 2016
Acute Pain - Pipeline by Shulov Innovative Science Ltd., H2 2016
Acute Pain - Pipeline by Syntrix Biosystems, Inc., H2 2016
Acute Pain - Pipeline by Thar Pharmaceuticals, Inc., H2 2016
Acute Pain - Pipeline by Trevena, Inc., H2 2016
Acute Pain - Pipeline by Yungjin Pharm. Co., Ltd., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Acute Pain - Dormant Projects, H2 2016
Acute Pain - Dormant Projects (Contd.1), H2 2016
Acute Pain - Dormant Projects (Contd.2), H2 2016
Acute Pain - Dormant Projects (Contd.3), H2 2016
Acute Pain - Dormant Projects (Contd.4), H2 2016
Acute Pain - Dormant Projects (Contd.5), H2 2016
Acute Pain - Dormant Projects (Contd.6), H2 2016
Acute Pain - Discontinued Products, H2 2016
Acute Pain - Discontinued Products (Contd.1), H2 2016

LIST OF FIGURES

Number of Products under Development for Acute Pain, H2 2016
Number of Products under Development for Acute Pain - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Top 10 Routes of Administration, H2 2016
Number of Products by Stage and Top 10 Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

AcelRx Pharmaceuticals, Inc.
Adynxx, Inc.
Amorsa Therapeutics Inc.
AnaBios Corporation
Anavex Life Sciences Corp.
AngioChem Inc.
Antibe Therapeutics, Inc.
AskAt Inc.
Cara Therapeutics, Inc.
Centrexion Therapeutics Corp
Charleston Laboratories, Inc.
ChironWells GmbH
Crescita Therapeutics Inc.
Cytogel Pharma, LLC
Dompe Farmaceutici S.p.A.
Grunenthal GmbH
Iroko Pharmaceuticals, LLC
KemPharm, Inc.
KPI Therapeutics, Inc.
Laboratorios Del Dr. Esteve S.A.
Mallinckrodt Plc
Nanomerics Ltd
Nanotherapeutics, Inc.
Orbis Biosciences Inc
Orexo AB
Orion Oyj
Pacira Pharmaceuticals, Inc.
Phosphagenics Limited
Recro Pharma, Inc.
Scilex Pharmaceuticals, Inc.
Shulov Innovative Science Ltd.
Syntrix Biosystems, Inc.
Thar Pharmaceuticals, Inc.
Trevena, Inc.
Yungjin Pharm. Co., Ltd.
Skip to top


Osteoarthritis Pain - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 212 pages

Ask Your Question

Acute Pain - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: